Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- Drug: Placebo for Rozibafusp Alfa
- First Posted Date
- 2019-08-15
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 244
- Registration Number
- NCT04058028
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸The Emory Clinic, Atlanta, Georgia, United States
🇺🇸Rheumatic Disease Clinical Research Center LLC, Houston, Texas, United States
A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant
- Conditions
- AllograftsRejection; Transplant, KidneyTransplant RejectionKidney Transplantation
- Interventions
- First Posted Date
- 2019-08-06
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 25
- Registration Number
- NCT04046549
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Keck Medical Center of USC, Los Angeles, California, United States
🇺🇸Duke University School of Medicine, Durham, North Carolina, United States
Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease
- Conditions
- Graves' OrbitopathyThyroid Eye Disease
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Amgen
- Registration Number
- NCT04040894
- Locations
- 🇺🇸
MACRO Trials, Beverly Hills, California, United States
🇺🇸Bascom Palmer Eye Institute, Miami, Florida, United States
🇺🇸NorthShore University HealthSystem, Skokie, Illinois, United States
A Study to Describe the Characteristics of Patients Treated With Apremilast for Plaque Psoriasis in Italian Routine Clinical Practice
- Conditions
- Plaque Psoriasis
- First Posted Date
- 2019-07-24
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 184
- Registration Number
- NCT04031027
- Locations
- 🇮🇹
Dermatologica e Venereologia Univ. A.O.U. Consorziale Policlinico, Bari, Italy
🇮🇹Dermatologia Ospedale Piero Palagi, Firenze, Italy
🇮🇹UOC Dermatologia Arcispedale Sant'Anna, Cona, Italy
Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout
- Conditions
- Gout
- Interventions
- Biological: PegloticaseDietary Supplement: folic acidDrug: placeboDrug: gout flare prophylaxis regimen
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 152
- Registration Number
- NCT03994731
- Locations
- 🇺🇸
Arizona Arthritis and Rheumatology Research, PLLC-East, Mesa, Arizona, United States
🇺🇸Axis Clinical Trials, Los Angeles, California, United States
🇺🇸Prohealth Research Center, Doral, Florida, United States
A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache
- Conditions
- Migraine Headache
- Interventions
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 620
- Registration Number
- NCT03971071
- Locations
- 🇦🇺
Holdsworth House Medical Practice, Sydney, New South Wales, Australia
🇺🇸Axiom Research, Colton, California, United States
🇭🇺Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz, Miskolc, Hungary
A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 24
- Registration Number
- NCT03969329
- Locations
- 🇬🇧
Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
🇧🇪Universitair Ziekenhuis Gent, Gent, Belgium
🇨🇿Fakultni nemocnice v Motole, Praha 5, Czechia
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
- Conditions
- Chemotherapy-induced Thrombocytopenia
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-05-03
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 162
- Registration Number
- NCT03937154
- Locations
- 🇺🇸
Saint Bernards Medical Center, Jonesboro, Arkansas, United States
🇺🇸Los Angeles Cancer Network, Anaheim, California, United States
🇺🇸University of California Irvine, Orange, California, United States
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma
- Conditions
- Relapsed Refractory Multiple Myeloma
- First Posted Date
- 2019-05-02
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 101
- Registration Number
- NCT03934684
- Locations
- 🇮🇳
Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Pondicherry, India
🇮🇳Cytecare Cancer Hospitals, Bengaluru, Karnataka, India
🇮🇳Thangam Cancer Centre, Namakkal, Tamil Nadu, India
A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2022-01-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 152
- Registration Number
- NCT03930186
- Locations
- 🇯🇵
Nippon Life Hospital, Osaka, Japan
🇯🇵Mita Dermatology Clinic, Minato-ku, Japan
🇯🇵Kume Clinic, Sakai-shi, Osaka, Japan